Pharmacological research progress of myocardial ischemia based on the metabonomics / 中国药学杂志

ABSTRACT

Cardiac hypo-function caused by myocardial ischemia is considered as the first killer of human health. The related metabolites in body can be changed due to the lack of blood and oxygen. These metabolites generated by pathological and physiology changes or exogenous intervention are extreme complicated, and the existing test methods can't satisfy the prospected purpose due to the lower sensitivity, more narrow liner range and so on. Therefore, the concept of metabonomics, a systemic analysis method, was put forward. Metabolites can be quantified in temporal and spatial dimension by metabonomics featured in a high throughput, higher detective sensitivity and wider liner range manner. So it has gradually been applied to many areas including myocardial ischemia. In this paper, based on the comprehensive research literature in domestic and overseas in recent years, the application of metabonomics in pharmacological research of myocardial ischemia was summarized. Five kinds of metabolic pathways are related with myocardial ischemia including sugar metabolism, energy metabolism, amino acid metabolism, purine metabolism and soluble epoxide hydrolase table oxidase P450 metabolism. Some drugs can be used to myocardial ischemia via these pathways. These representative drugs and their mechanisms which are analyzed by metabonomics were concluded in this paper.